3个月与12个月罗莫索单抗治疗绝经后骨质疏松:LIDA非劣效随机对照试验
LIDA试验在50例高骨折风险的绝经后女性中比较3个月罗莫索单抗后序贯9个月地舒单抗与12个月罗莫索单抗的疗效。主要终点为全髋骨密度变化百分比,非劣效界值2%。
要点
- 3个月罗莫索单抗序贯9个月地舒单抗在提高全髋骨密度方面非劣效于12个月方案。
- 不良事件(背痛、咳嗽、乏力等)在两组间均衡。
核心结论
- 在高骨折风险的绝经后女性中,3个月罗莫索单抗后序贯9个月地舒单抗在增加全髋骨密度方面非劣效于12个月罗莫索单抗。
研究设计与样本
- 为期12个月的前瞻性、开放标签、随机、对照、非劣效性试验,在美国单一学术医疗中心进行,纳入50例高骨折风险的绝经后女性。
- 参与者随机分配至3个月罗莫索单抗组(210 mg皮下注射,每月一次,随后9个月地舒单抗60 mg皮下注射,每6个月一次)或12个月罗莫索单抗组。
- 主要终点为全髋骨密度变化百分比,非劣效界值设为2%。
主要发现
- 不良事件(背痛、咳嗽、乏力、头痛、关节痛、肌肉痉挛、肌肉疼痛、心悸、感觉异常、注射部位反应、流涕、皮疹、肿胀)在两组间均衡。
关键数值与推荐
- 非劣效界值为2%,主要终点为全髋骨密度变化百分比。
临床怎么用
- 鉴于罗莫索单抗的费用、注射负担和潜在不良反应,缩短疗程的方案可能扩大这一独特有效疗法的可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postmenopausal osteoporosis is a highly prevalent disease associated with substantial morbidity and mortality. The most recently introduced osteoporosis medication is romosozumab, a monoclonal antibody with a unique mechanism of action that increases bone mineral density (BMD) more than other agents by both stimulating new bone formation and inhibiting resorption. The drug's stimulation of bone formation, however, wanes after several months. The use of romosozumab is limited by cost, the inconvenience of monthly clinic-administered injections, and its cardiovascular risk profile. In this trial, we aimed to test the hypothesis that a shorter course of romosozumab might be equally effective as the standard regimen. METHODS: We did a 12-month, prospective, open-label, randomised, controlled, non-inferiority trial of 50 postmenopausal women at high risk of fracture. The study was done at a single academic medical centre in the USA. Participants were randomly assigned to receive 3 months of romosozumab (210 mg by subcutaneous injection, monthly) followed by 9 months of denosumab (60 mg by subcutaneous injection, every 6 months; 3-month ROMO group) or 12 months of romosozumab (12-month ROMO group). The primary endpoint was the percentage change in total hip BMD. The non-inferiority threshold was set at 2%. The trial was registered at ClinicalTrials.gov, NCT05010590. FINDINGS: Between March 2, 2022, and May 2, 2023, we screened 188 participants. Of those, 102 (54%) were ineligible and 36 (19%) declined to participate. We randomly assigned 50 participants to either the 3-month ROMO group (24 [48%] participants) or the 12-month ROMO group (26 [52%] participants). Study participants completing at least one post-baseline visit were included in the analysis (modified intention-to-treat analysis). The mean age of participants was 69·6 years (SD 4·5). The mean 12-month change in total hip BMD was 5·7% (SD 3·3) in the 3-month romosozumab group and 6·0% (3·2) in the 12-month romosozumab group, meeting the prespecified non-inferiority threshold. Adverse events (back pain, cough, fatigue, headache, joint pain, muscle cramps, muscle pain, palpitations, paraesthesia, reaction at injection site, rhinorrhoea, skin rash, and swelling) were balanced between groups. INTERPRETATION: In postmenopausal women at high risk of fracture, 3 months of romosozumab followed by 9 months of denosumab was non-inferior to 12 months of romosozumab in increasing total hip BMD. Given the expense, injection burden, and potential adverse effects of romosozumab, this abbreviated approach could broaden access to this uniquely effective therapy. FUNDING: US National Institute of Arthritis and Musculoskeletal and Skin Diseases and US National Center for Advancing Translational Science.
引用
- Leder BZ, Ramchand SK, Jordan M, et al. 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. Lancet Diabetes Endocrinol. 2026. PMID: 41621431. doi:10.1016/S2213-8587(25)00319-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。